A prospective, multicenter, double-randomised, double-blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to gemcitabine in combination with placebo, followed as second line treatment by masitinib in combination with Folfiri.3 versus placebo in combination with Folfiri.3 in the treatment of patients with non resectable locally advanced or metastatic pancreatic cancer.

Trial Profile

A prospective, multicenter, double-randomised, double-blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to gemcitabine in combination with placebo, followed as second line treatment by masitinib in combination with Folfiri.3 versus placebo in combination with Folfiri.3 in the treatment of patients with non resectable locally advanced or metastatic pancreatic cancer.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Masitinib (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 12 Jul 2017 Accordign to a AB Science media release, the compan expects and interim analys by the end of 2017.
    • 15 Jun 2017 This trial has been suspended in Germany.
    • 06 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top